The study tested BMS’ Opdivo with concurrent chemoradiotherapy followed by both Opdivo and Yervoy or Opdivo by itself. Researchers compared outcomes from that cohort to chemoradiotherapy followed by durvalumab.
Opdivo has about two dozen approved cancer indications, with some of them including antibody Yervoy. This trial focused on 925 patients with unresectable stage III non-small cell lung cancer.
The drugmaker said it will work with investigators to share more findings from the study.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
